RxDoctor Payments Data

Mita Gupta, MD

Internal Medicine · Brewster, MANPI 1750390894

Payments from drug & device makers

$997in general payments, 2019–2025

Across 44 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$146
  • Novo Nordisk$104
  • Novartis$101
  • AbbVie$89
  • Lemaitre Vascular, Inc.$82
  • Bayer$66
  • plus $409 from 15 others

What the payments were for

  • Food & beverage$997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$997 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$416,901
Medicare patients
815
Services billed
10,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$203,434
JardianceEmpagliflozin118$76,362
MounjaroTirzepatide39$47,331
OzempicSemaglutide43$43,162
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$36,972
TrulicityDulaglutide26$36,438
XareltoRivaroxaban48$23,152
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$20,882
GemtesaVibegron77$15,024
TradjentaLinagliptin18$14,015
Combivent RespimatIpratropium/Albuterol Sulfate25$13,072
Incruse ElliptaUmeclidinium Bromide29$11,961
Rosuvastatin Calcium347$11,424
Atorvastatin Calcium740$10,006
Breo ElliptaFluticasone/Vilanterol24$9,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$203,434385 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat$29$109,365173 claims
Lilly USA, LLCMounjaro, Trulicity$19$83,76965 claims
Novo NordiskOzempic$104$43,16243 claims
Johnson & JohnsonXarelto$28$23,15248 claims
AbbVieSynthroid$89$7,93986 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$29$5,327657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Brewster

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →